AIM ImmunoTech Inc. Common Stock AIM 深 沪
等待开盘 01-23 09:30:00 美东时间
1.26
+0.090
+7.69%
华盛通- 最 高1.28
- 今 开1.18
- 成交量 11.15万股
- 最 低 1.15
- 昨 收 1.17
- 总市值 370.64万
- 52周最高 20.3297
- 市盈率 静 --
- 换手率 3.79%
- 52周最低 1.0689
- 委 比 -68.83%
- 总股本 294.16万
- 历史最高 20.3297
- 量 比 0.96
- 振 幅 11.11%
- 历史最低 1.0689
- 每 手 1
- 风险率 2.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AIM ImmunoTech Declares 1-For-1,000 Stock Dividend For Shareholders And Option/Warrant Holders
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every
2025-12-31 06:20
AIM ImmunoTech Announces Stock Dividend
AIM ImmunoTech Inc. (NYSE American: AIM) announced a stock dividend of one share of common stock for every 1,000 shares outstanding and one share for every outstanding option or warrant. The dividend will be issued to shareholders and Alternate Securities holders of record as of January 9, 2026, and distributed to DTCC on January 13, 2026. Fractional shares will be rounded down, with remaining fractions paid in cash based on a $1.305 per-share pr...
2025-12-30 22:10
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. has published a new CEO Corner segment on its website, where Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen® (rintatolimod), which is currently being evaluated in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca’s Imfinzi® (durvalumab). For more details, visit the company’s website.
2025-12-10 14:00
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $22
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $24 to $22.
2025-12-08 18:33
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
AIM ImmunoTech的CEO Thomas K. Equels将在12月4日参与Virtual Investor Closing Bell Series活动，重点讨论Ampligen的临床和监管策略，包括与AstraZeneca合作的DURIPANC试验及与Merck合作的卵巢癌试验。投资者可通过aim@jtcir.com提交问题，活动将在aimimmuno.com进行直播。
2025-12-01 13:55
AIM ImmunoTech Q3 EPS $(1.57) Misses $(0.98) Estimate, Sales $26.000K Down From $35.000K YoY
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(1.57) per share which missed the analyst consensus estimate of $(0.98) by 59.39 percent. This is a 73.83 percent increase over losses of $(6.00) per share from the
2025-11-18 21:57
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
AIM ImmunoTech Inc. reportedProgress in Cancer Therapy and Positive Financial Developments for Q3 2025
2025-11-18 13:55
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
